학술논문
Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study.
Document Type
Letter
Author
Source
Subject
*TYPE 2 diabetes
*CHRONIC kidney failure
*CARDIOGENIC shock
*COHORT analysis
*MEDICAL research
*MORTALITY
*
*
*
*
*
Language
ISSN
0149-5992
Abstract
The article focuses on oral hypoglycemic agents (OHA) are not recommended for patients with advanced chronic kidney disease (CKD) and use of supplemental insulin has potentially increase the risk of hypoglycemia and cardiovascular events has noted among patients with limited choices. Topics include the pioglitazone being a thiazolidinedione be safely used in patients with CKD, and the patients with end-stage renal disease (ESRD) without dose adjustment.